Trial Profile
A pivotal phase III trial of Proxinium (VB4-847) in patients with head and neck cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 25 Jun 2015
Price :
$35
*
At a glance
- Drugs Oportuzumab monatox (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 25 Jun 2015 New trial record
- 23 Jun 2015 As per a Viventia biotechnologies media release, the study is scheduled to begin in Q4 2015.